The UK has become the world’s fourth largest exporter, but can it maintain this momentum? 
South Korea Pledges 5-Year Boost in Console Gaming Market Share 
Inflation is slowly falling, while student debt is climbing: 6 graphs that explain today’s CPI 
Kakao Gets Approval to Acquire SM Entertainment Controlling Stake 
Toyota to Accelerate Advancement of Fuel Cell Technology, Establishes Hydrogen Headquarters 
Kroger, Disney+ Considering Partnership to Add Streaming Service to Grocery Delivery Program 
How India’s economy has fared under ten years of Narendra Modi 
Boeing’s Starliner is about to launch − if successful, the test represents an important milestone for commercial spaceflight 
Tesla Granted South Korean Emission Credit Trading Rights by Environmental Ministry 
Nigerians throw naira notes around to show love: but it could land you in jail 
Why is the London Stock Exchange losing out to the US 
The yen plunges to 34-year low despite interest rate hike 
Booking Holdings Surpasses Wall Street Expectations with Strong Q1 Earnings Amidst Global Travel Surge 
Taylor Swift, Justin Bieber, Billie Eilish Universal Music Label Signs New Deal With TikTok, Ending Dispute 
Electric air taxis are on the way – quiet eVTOLs may be flying passengers as early as 2025 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
